Assertio Holdings Inc
ASRT0.748USD
-0.003-0.35%
Market hours （ET）Quotes delayed by 15 min
71.93MMarket Cap
LossP/E TTM
More Details of Assertio Holdings Inc Company
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Assertio Holdings Inc Info
Ticker SymbolASRT
Company nameAssertio Holdings Inc
IPO dateFeb 12, 1997
CEOMr. Brendan P. O'Grady
Number of employees58
Security typeOrdinary Share
Fiscal year-endFeb 12
Address100 S. Saunders Road
CityLAKE FOREST
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code60045
Phone12244197106
Websitehttps://www.assertiotx.com/
Ticker SymbolASRT
IPO dateFeb 12, 1997
CEOMr. Brendan P. O'Grady
Company Executives of Assertio Holdings Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Mr. Mark L. Reisenauer
Mr. Mark L. Reisenauer
Chief Executive Officer, Director
Chief Executive Officer, Director
53.75K
--
Ms. Heather L. Mason
Ms. Heather L. Mason
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sigurd C. (Sig) Kirk
Mr. Sigurd C. (Sig) Kirk
Independent Director
Independent Director
--
--
Mr. Sravan K. Emany
Mr. Sravan K. Emany
Independent Director
Independent Director
--
--
Ms. Mary E Pietryga
Ms. Mary E Pietryga
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Ajay Patel
Mr. Ajay Patel
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
196.85K
+12.05%
Mr. Paul Schwichtenberg
Mr. Paul Schwichtenberg
Executive Vice President, Chief Transformation Officer
Executive Vice President, Chief Transformation Officer
167.52K
+14.47%
Mr. Sam Schlessinger
Mr. Sam Schlessinger
Executive Vice President, General Counsel
Executive Vice President, General Counsel
156.13K
+17.33%
Mr. David Matthew Stark
Mr. David Matthew Stark
Independent Director
Independent Director
107.50K
+100.00%
Mr. William T. Mckee
Mr. William T. Mckee
Independent Director
Independent Director
97.28K
+123.48%
Mr. Mark L. Reisenauer
Mr. Mark L. Reisenauer
Chief Executive Officer, Director
Chief Executive Officer, Director
53.75K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
ROLVEDON
16.13M
55.19%
other
4.44M
15.20%
Sympazan
3.24M
11.10%
INDOCIN products
3.03M
10.38%
SPRIX Nasal Spray
1.98M
6.76%
Royalties and milestone revenue
400.00K
1.37%
By RegionUSD
Name
Revenue
Proportion
United States
29.22M
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ROLVEDON
16.13M
55.19%
other
4.44M
15.20%
Sympazan
3.24M
11.10%
INDOCIN products
3.03M
10.38%
SPRIX Nasal Spray
1.98M
6.76%
Royalties and milestone revenue
400.00K
1.37%
Shareholding Stats
Updated: Sun, Aug 17
Updated: Sun, Aug 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
9.15%
The Vanguard Group, Inc.
4.56%
Renaissance Technologies LLC
2.93%
BlackRock Institutional Trust Company, N.A.
1.43%
Geode Capital Management, L.L.C.
1.06%
Other
80.87%
Shareholders
Shareholders
Proportion
Nantahala Capital Management, LLC
9.15%
The Vanguard Group, Inc.
4.56%
Renaissance Technologies LLC
2.93%
BlackRock Institutional Trust Company, N.A.
1.43%
Geode Capital Management, L.L.C.
1.06%
Other
80.87%
Shareholder Types
Shareholders
Proportion
Hedge Fund
14.08%
Investment Advisor
9.33%
Investment Advisor/Hedge Fund
3.41%
Individual Investor
2.61%
Research Firm
0.05%
Venture Capital
0.01%
Other
70.51%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
269
25.82M
26.82%
-22.80M
2025Q2
311
28.52M
29.77%
-30.86M
2025Q1
337
28.16M
29.40%
-32.55M
2024Q4
339
31.00M
32.47%
-30.41M
2024Q3
330
33.06M
34.86%
-33.72M
2024Q2
326
40.98M
43.17%
-33.17M
2024Q1
316
48.96M
52.78%
-20.37M
2023Q4
308
49.49M
53.68%
-10.26M
2023Q3
295
49.25M
53.86%
+8.83M
2023Q2
258
36.71M
65.25%
+1.46M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Nantahala Capital Management, LLC
8.81M
9.15%
+370.31K
+4.39%
Jun 30, 2025
The Vanguard Group, Inc.
4.38M
4.56%
--
--
Jun 30, 2025
Renaissance Technologies LLC
2.82M
2.93%
+117.69K
+4.35%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.37M
1.43%
-11.56K
-0.83%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.02M
1.06%
-86.31K
-7.79%
Jun 30, 2025
Two Sigma Investments, LP
867.90K
0.9%
-357.19K
-29.16%
Jun 30, 2025
CM Management, LLC
724.38K
0.75%
+249.38K
+52.50%
Jun 30, 2025
Millennium Management LLC
694.52K
0.72%
-90.05K
-11.48%
Jun 30, 2025
Polen Capital Management, LLC
651.61K
0.68%
-129.46K
-16.57%
Sep 30, 2024
Peisert (Daniel A)
607.46K
0.63%
--
--
Mar 13, 2025
View more
Related ETFs
Updated: 7 hours ago
Updated: 7 hours ago
Name
Proportion
ALPS Barron's 400 ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
Proshares Ultra Russell 2000
0%
Lattice Hartford Multifactor Small Cap ETF
0%
Fidelity Small-Mid Multifactor ETF
0%
iShares Russell 3000 ETF
0%
View more
ALPS Barron's 400 ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Royce Quant Small-Cap Quality Value ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Lattice Hartford Multifactor Small Cap ETF
Proportion0%
Fidelity Small-Mid Multifactor ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
Date
Type
Ratio
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
May 17, 2021
Merger
4→1
